Coherus BioSciences, Inc. Forecast, price target & analysts
Coherus BioSciences, Inc. Target price 2026 - Analyst rating & recommendation
Coherus BioSciences, Inc. Classifications & Recommendation
Coherus BioSciences, Inc. Price Target
| Target Price | $7.14 |
| Price | $1.13 |
| Potential |
531.86%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Coherus BioSciences, Inc. 2027 .
The average Coherus BioSciences, Inc. target price is $7.14.
This is
531.86%
register free of charge
$10.50
829.20%
register free of charge
$4.04
257.52%
register free of charge
|
|
| A rating was issued by 12 analysts: 10 Analysts recommend Coherus BioSciences, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Coherus BioSciences, Inc. stock has an average upside potential 2027 of
531.86%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 42.17 | 61.03 |
| 59.80% | 44.71% | |
| EBITDA Margin | -400.31% | -222.30% |
| 41.60% | 44.47% | |
| Net Margin | 398.43% | -214.45% |
| 268.81% | 153.82% |
8 Analysts have issued a sales forecast Coherus BioSciences, Inc. 2026 . The average Coherus BioSciences, Inc. sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Coherus BioSciences, Inc. EBITDA forecast 2026. The average Coherus BioSciences, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
9 Coherus BioSciences, Inc. Analysts have issued a net profit forecast 2026. The average Coherus BioSciences, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 1.43 | -0.85 |
| 495.83% | 159.44% | |
| P/E | negative | |
| EV/Sales | 1.98 |
9 Analysts have issued a Coherus BioSciences, Inc. forecast for earnings per share. The average Coherus BioSciences, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Coherus BioSciences, Inc....
Current Coherus BioSciences, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Guggenheim |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| Guggenheim |
Locked
➜
Locked
|
Locked | May 11 2026 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | Jan 22 2026 |
| Maxim Group |
Locked
➜
Locked
|
Locked | Sep 04 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 29 2025 |
| UBS |
Locked
➜
Locked
|
Locked | Apr 24 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 11 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Guggenheim:
Locked
➜
Locked
|
Aug 07 2026 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
May 11 2026 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Jan 22 2026 |
|
Locked
Maxim Group:
Locked
➜
Locked
|
Sep 04 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 29 2025 |
|
Locked
UBS:
Locked
➜
Locked
|
Apr 24 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 11 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
